Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP ‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach-Reference-Cited by-同舟云学术

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP ‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

Published:2019-05-12 Issue:7 Volume:8 Page:489-499
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Zhou Diansong¹,Podoll Terry²,Xu Yan²,Moorthy Ganesh¹,Vishwanathan Karthick¹,Ware Joseph²,Slatter J. Greg²,Al‐Huniti Nidal¹

Affiliation:

1. Quantitative Clinical Pharmacology Early Clinical Development IMED Biotech Unit AstraZeneca Boston Massachusetts USA

2. DMPK/Clinical Pharmacology Acerta Pharma South San Francisco California USA

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12408

Reference31 articles.

1. Mechanisms of B-cell lymphoma pathogenesis

2. Lymphoid Malignancies: the dark side of B-cell differentiation

3. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

4. Targeting Bruton's tyrosine kinase in B cell malignancies

5. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Simple HPLC–UV‐Based Bioanalytical Method for Estimation of Acalabrutinib in Rat Plasma and Its Application in Evaluation of Drug‐Loaded Nanocrystal Formulation;SEPARATION SCIENCE PLUS;2024-08-15

2. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

3. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab;CPT: Pharmacometrics & Systems Pharmacology;2023-12-14

4. Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics;Pharmaceutics;2023-12-04

5. Regulatory Considerations in Metabolism‐ and Transport‐Based Drug Interactions;Oral Bioavailability and Drug Delivery;2023-10-10